GlaxoSmithKline’s (GSK’s) portfolio of respiratory Ellipta products, including Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), is experiencing strong increases in demand (approximately 20% in the second quarter of 2018). To meet the demand, the company has added a new manufacturing facilityat its site in Montrose, Scotland, which opened in October 2018.
The $69 million addition will produce the active ingredients used in GSK Ellipta inhalers. The other plant producing these products is located in Singapore. Other products in the portfolio include Anoro (umeclidinium/vilanterol), Incruse (umeclidinium), Breo/Relvar (fluticasone furoate/vilanterol) and Arnuity (fluticasone). As with Trelegy, they are delivered using the Ellipta dry powder inhaler.
The company established a second site for production of its respiratory active pharmaceutical ingredients to ensure a stable global supply to meet growing demand.
Emilie is responsible for strategic content development based on scientific areas of specialty for Nice Insight research articles and for assisting client content development across a range of industry channels. Prior to joining Nice Insight, Emilie worked at a strategy-based consulting firm focused on consumer ethnographic research. She also has experience as a contributing editor, and has worked as a freelance writer for a host of news and trends-related publications